Targeting the CD47-SIRPA Axis in Oncology: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More

Targeting the CD47-SIRPA Axis in Oncology: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More

Targeting the CD47-SIRPα axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates.

Most of the identified molecules in this report are either anti-CD47 antibodies or SIRPα-Fc recombinant proteins. In healthy cells, CD47 serves as a ""don’t eat me"" signal by binding to the transmembrane SIRPα protein on phagocytic cells, preventing the engulfment of ""self"" by macrophages. In several cancer types, tumor cells overexpress CD47 to elude the immune system. Exploration of this property has been the driving force to attract hundreds of million of dollars in investments to companies like Tioma Therapeutics, Surface Oncology and Forty Seven, the latter of which has just recently completed a $113 million IPO of its common stock on June 26th, 2018. Deals in this area include the early adopter move in 2012 by Celgene securing Inhibrx’ anti-CD47 antibody in a $500 million dollar deal to the recent billion dollar plus agreement between OSE Immunotherapeutics and Boehringer Ingelheim.

On the clinical development front, this report identifies fewer than ten molecules targeting the CD47-SIRPα axis which have made it into the clinic and so far with encouraging results. Several of these trials also shed light on biomarker- and combination therapies of interest. On the horizon, this field will soon have another injection of candidate therapies with bispecific CD47 antibodies entering the clinic in late 2018 or early 2019.

Moreover, targeting the CD47-SIRPα axis also has the potential to become the combination therapy of choice as has already been demonstrated via mediating longer survival in mice together with oncolytic virotherapy and enhancing phagocytic capacity when used together with Carisma Therapeutics’ CAR macrophages. Carisma Therapeutics themselves have just announced a $53 million series A round of financing in order to develop its novel CAR macrophage cellular immunotherapy and is estimating that their project(s) will enter into the clinic in 2019.

Key Topics & Reasons to buy:

This report consists of highly-visual infographics, facilitating your understanding of the data and insights from analysis of over 35 CD47-SIRPα based therapies in cancer. These therapies range from discovery to Phase II clinical development.

Types of graphical analyses include: Funnel diagrams, Pie charts, Bar diagrams

You get unique, actionable insights that power your understanding of the CD47-SIRPα based therapies identified in this report. For example: Recent Clinical Trial Results, Clinical Biomarkers, Combination Therapies, Deals & Alliances, Startup Companies, Bispecific Drugs, Pursued Tumor Types, Disease Target Analysis, Latest Advancement through Five Major/Influential Cancer Meetings etc.

You get full access to and can export data from Detailed Drug Profiles, Target Profiles and Company Profiles incl. Business Development and Licensing contacts.

You have a good value and easy to use ""Go-To"" tool that allows you to benchmark your decision making and minimizes the danger of having blindspots in your coverage of the CD47-SIRPα landscape

Continually updated throughout the reports lifetime with the latest activities and developments in the field

Format, Free Updates & Pricing

This is 12 months of access to an ever-green report that you access simply online. It is continuously updated with new information and analysis throughout your 12 month access period, ensuring that you stay up to date with this fast moving field. You can customise and export graphs and tables to download and use in your own presentations, slides and reports."Online Access

1 CD47-SIRPα Based Therapies in Oncology: An Overview
1.1 Current Developmental Stage & Status of CD47-SIRPα Based Therapies
1.2 Timeline Development Review of CD47-SIRPα Based Therapies
1.3 Compound Types Targeting the CD47-SIRPα Axis: From Small Molecules to Antibodies
1.4 Disease Target Analysis of CD47-SIRPα Based Therapies: Target
1.4.1Target Profiles
1.5 Pursued Tumor Types
1.6 Recent Clinical Trial Results from CD47-SIRPα Based Therapies
1.7 Clinical Biomarkers in Play among CD47-SIRPα Based Therapies
1.8 Combination Therapies with CD47-SIRPα Based Therapies
1.9 CD47-SIRPα Based Therapies with Orphan Drug Designation
1.10 2017-2018 CD47-SIRPα Based Therapies Advancement Through the Lenses of Five Major/Influential Cancer Meetings: Selected Abstracts
1.10.1 AACR
1.10.2 ASCO
1.10.4 EHA
1.10.5 SITC
1.11 Stakeholders in CD47-SIRPα Based Therapies: Part I Originators/Owners
1.12 Stakeholders in CD47-SIRPα Based Therapies: Part II Licensors/Collaborators
1.13 Business Development & Licensing Contacts
1.14 Drug Profiles
2 Startups Targeting the CD47-SIRPα Axis
3 Bispecific Drugs Targeting the CD47-SIRPα Axis
4 Deals & Alliances Among CD47-SIRPα Targeting Drugs
5 Phase II Pipeline Review & Analysis of CD47-SIRPα Based Therapies
6 Phase I Pipeline Review & Analysis of CD47-SIRPα Based Therapies
7 Preclinical Pipeline Review & Analysis of CD47-SIRPα Based Therapies
8 Discovery Pipeline Review & Analysis of CD47-SIRPα Based Therapies
9 CD47-SIRPα Based Therapies in Solid Tumors
10 CD47-SIRPα Based Therapies in non-Hodgkin’s Lymphoma
11 CD47-SIRPα Based Therapies in Acute Myelogenous Leukemia
12 CD47-SIRPα Based Therapies in Acute Lymphocytic Leukemia
13 CD47-SIRPα Based Therapies in Myeloma

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings